Letters Food and Drug Administration

Surveillance and medical devices

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c6999 (Published 07 December 2010) Cite this as: BMJ 2010;341:c6999
  1. Alun Tomkinson, consultant ear, nose, and throat surgeon 1,
  2. Wendy Harrison, senior scientist 2,
  3. Mark Temple, consultant in public health medicine3,
  4. Peter Phillips, director4
  1. 1Department of Otolaryngology Head and Neck Surgery, University Hospital Wales, Cardiff CF14 4XW, UK
  2. 2Surgical Instrument Surveillance Programme (SISP), Public Health Service for Wales, Cardiff CF10 3NW, UK
  3. 3Communicable Disease Surveillance Centre, Public Health Service for Wales
  4. 4Surgical Materials Testing Laboratory, Princess of Wales Hospital, Bridgend CF31 1RQ, UK
  1. tomkinsona@cardiff.ac.uk

Lenzer and Brownlee highlight the potential value for postmarketing surveillance,1 but this is true not only for “complex” or new devices.

The UK government’s decision in 2001 to replace reusable tonsillectomy instruments with single use devices, because of the risk from variant Creutzfeldt-Jakob disease, is a lesson in point. These were not …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe